NFKB2 Antibody (OAAB18272)

Catalog No: OAAB18272

Size:100ul

Western blot analysis of lysate from Hela cell line, using NF-KB p100/p52 Antibody (Ab-869) (B7165).
B7165 was diluted at 1:1000.
A goat anti-rabbit IgG H&L (HRP) at 1:5000 dilution was used as the secondary antibody.
Lysate at 35ug.
Dilution: 1:1000

Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using NF-kappaB p100/p52 (Ab-869) Antibody.
Dilution: 1:50-1:100

Product Info

• Predicted Species Reactivity: Human, Mouse, Rat
• Product Format: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Clonality: Polyclonal
• Isotype: Rabbit Ig
• Host: Rabbit
• Application: WB, IHC
• Reconstitution and Storage: Maintain refrigerated at 2-8C for up to 2 weeks. For long term storage store at -20C in small aliquots to prevent freeze-thaw cycles.
• Application Info: WB: 1:1000
  IHC: 1:50~1:100
• Reference: Schmid R.M., et al.Nature 352:733-736(1991).
  Bours V., et al.Mol. Cell. Biol. 12:685-695(1992).
  Thakur S., et al.Oncogene 9:2335-2344(1994).
  Rabson A.B., et al.Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
  Kalnine N., et al.Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.

Target Info

• Gene Symbol: NFKB2
• Alias Symbols: p52, p100, H2TF1, LYT10, CVID10, LYT-10, NF-kB2, p49/p100
• NCBI Gene Id: 4791
• Description of Target: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14- activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.
• Uniprot ID: Q00653
• Molecular Weight: 97 kDa